First human test for new drug targeting devastating genetic immune diseases
NCT ID NCT07364513
Summary
This is a very early study to check the safety of a new drug called IMSB301 in people with rare, lifelong genetic conditions known as type 1 interferonopathies. The study will enroll about 6 patients, aged 12 and up, who have specific genetic mutations. Researchers will give participants the drug daily for 28 days and closely monitor them for any side effects and to see how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 INTERFERONOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Children's Hospital at Westmead
RECRUITINGSydney, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.